MASH and Liver Health
Join us in a study to explore a new treatment that may help improve liver health for those with MASH and specific fibrosis stages. We want to see how safe and effective this treatment is compared to a placebo.
Study site: NeoClinical Research
- Fatty liver disease (MASH/NASH)
Recruiting
Male/Female
18 - 75 years of age
TBD
- About the Study
- In this study, we will look at how a new treatment can help resolve liver inflammation and improve overall liver health for individuals with MASH and specific fibrosis stages.
- What does the study involve?
- Participants will receive either the new treatment or a placebo. All treatments will be given through injections.
What to expect
- Placebo
- You may receive a placebo (a look-alike with no active medicine).
- Which treatment you get
- Chosen at random. Neither you nor the study team will know which treatment you get.
- Who can participate?
- We're looking for adults aged 18–75 who have MASH with confirmed F2 or F3 fibrosis. You should have a history of metabolic syndrome. Some health conditions may prevent participation. Think you might qualify? Apply to find out!
Where is the study taking place?
Palmetto Medical Plaza
Study details
- Sponsor
- GlaxoSmithKline
- Phase
- Phase 3: confirming it works in a large group, often against current treatment
- Dates
- October 2025 to December 2031 (expected)
- Size
- 1200 participants across all sites
- Healthy volunteers
- Only people with the condition
Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
One moment…
About NeoClinical Research
NeoClinical Research is a leading, multi-therapeutic clinical research center based in South Florida that bridges the gap between leading pharmaceutical companies and diverse patient populations.